公开(公告)号：US20240344241A1

公开(公告)日：2024-10-17

申请号：US18701094

申请日：2022-10-14

申请人： THE UNIVERSITY OF QUEENSLAND ,  The University of Tokyo

发明人： David James CRAIK ,  Simon John DE VEER ,  Yen-Hua HUANG ,  Joakim Erik SWEDBERG ,  Hiroaki SUGA ,  Wenyu LIU ,  Toby PASSIOURA

IPC分类号： C40B30/04 ,  C12N15/10 ,  C12Q1/02 ,  C12R1/19 ,  G01N33/68

CPC分类号： C40B30/04 ,  C12N15/1062 ,  C12Q1/02 ,  G01N33/6845 ,  C12R2001/19 ,  G01N2500/04

摘要： Disclosed are proteinaceous coagulation factor XIIa (FXIIa) inhibitors and their use for treating or inhibiting the development of a condition in which inhibiting FXIIa stimulates or effects treatment or inhibition of the development of the condition. Suitable conditions include thromboembolism-associated conditions such as acute coronary syndrome, stroke, deep vein thrombosis and pulmonary embolism, a thrombosis, a thrombosis-associated hematologic disorder such as sickle cell disease or thrombophilia, and an inflammatory condition or a condition related to the kallikrein-kinin system such as hereditary angioedema, multiple sclerosis, rheumatoid arthritis or lupus. The proteinaceous FXIIa inhibitors are also useful for treating or inhibiting thrombus and/or embolus formation. In vitro methods for identifying a disulfide rich peptide which binds to a target substance are also disclosed.